1. Home
  2. ASIX vs ARVN Comparison

ASIX vs ARVN Comparison

Compare ASIX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdvanSix Inc.

ASIX

AdvanSix Inc.

HOLD

Current Price

$20.22

Market Cap

600.1M

Sector

Industrials

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.42

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASIX
ARVN
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
600.1M
516.2M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
ASIX
ARVN
Price
$20.22
$8.42
Analyst Decision
Buy
Buy
Analyst Count
2
19
Target Price
$26.00
$15.05
AVG Volume (30 Days)
201.9K
658.9K
Earning Date
05-08-2026
05-04-2026
Dividend Yield
2.62%
N/A
EPS Growth
11.11
58.84
EPS
N/A
1.70
Revenue
$1,684,625,000.00
$262,600,000.00
Revenue This Year
$4.19
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
45.49
N/A
52 Week Low
$14.10
$6.06
52 Week High
$26.73
$14.22

Technical Indicators

Market Signals
Indicator
ASIX
ARVN
Relative Strength Index (RSI) 45.81 54.99
Support Level $19.22 $8.37
Resistance Level $20.48 $8.90
Average True Range (ATR) 0.77 0.37
MACD -0.05 0.06
Stochastic Oscillator 26.91 36.18

Price Performance

Historical Comparison
ASIX
ARVN

About ASIX AdvanSix Inc.

AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: